Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glenmark Pharma Inks Deal With MeyerZall Labs (India)

This article was originally published in PharmAsia News

Executive Summary

Glenmark Pharmaceuticals Ltd, one of India's biggest pharmaceutical companies, is teaming up with the South Africa-based MeyerZall Laboratories. The deal stretches for a period of 10 years. Over that time the two companies will work together to expand drugs in Glenmark's topical dermatology pipeline. These treatments will primarily focus on aiding patients suffering from psoriasis, fungal infections, and inflammation. Thanks to the new partnership, Glenmark and MeyerZall will be able to offer the largest range of topical dermatology products in South Africa. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts